Pre-Made Lerodalcibep Biosimilar, Fusion Protein targeting PCSK9 fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting FH3/FHCL3/HCHOLA3/LDLCQ1/NARC-1/NARC1/PC9 for drug discovery and mechanism of action (MOA) research

Pre-Made Lerodalcibep Biosimilar, Fusion Protein targeting PCSK9 fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting FH3/FHCL3/HCHOLA3/LDLCQ1/NARC-1/NARC1/PC9 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lerodalcibep is a recombinant fusion protein of a proprotein convertase subtilsin-kexin type 9 (PCSK9)-binding domain (adnectin) and human serum albumin (HAS). Binding of adnectin to PCSK9 prevents the interaction between PCSK9 and the LDL receptor. Linkage of HAS to the adnectin increases the half-life of 12 to 15 days. PCSK9 inhibitors are a new class of drugs that lower LDL, or “bad,” cholesterol. These agents target and inactivate proprotein convertase subtilsin-kexin type 9 (PCSK9), a hepatic protease that attaches and internalizes LDL receptors into lysosomes hence promoting their destruction.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-890-1mg	1mg	3090
GMP-Bios-INN-890-10mg	10mg	Inquiry
GMP-Bios-INN-890-100mg	100mg	Inquiry
GMP-Bios-INN-890-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Lerodalcibep Biosimilar, Fusion Protein targeting PCSK9 fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting FH3/FHCL3/HCHOLA3/LDLCQ1/NARC-1/NARC1/PC9
INN Name	Lerodalcibep
Target	PCSK9
Format	Fusion Protein
Derivation	synthetic construct
Species Reactivity	human
CH1 Isotype	Fusion - Alternative to antigen receptors (domain scaffold: FN1 F10, fibronectin domain F10)
VD LC	Fusion - Alternative to antigen receptors (domain scaffold: FN1 F10, fibronectin domain F10)
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	LIB Therapeutics, LLC (Cincinnati OH USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	Alternative to antigen receptors, domain scaffold FN1 F10, fibronectin F10 (Adnectin™)